Gapping up
In reaction to strong earnings/guidance:
- KNL +13%, GPK +8.6%, CAT +6.7%, PII +5.7%, GM +4.2%, HMST +3.8%, CR +3.4%, CLB +3.4%, CIT +3.2%, AMTD +3%, CAJ +2.9%, LLY +2.7%, FCAU +2.5%, MMM +2.5%, SWK +1.9%, YNDX +1.6%, PCAR +1%, UTX +0.7%
M&A news:
- HES +2.9% (Hess to sell its interests in offshore Equatorial Guinea to Kosmos Energy (KOS) and Trident Energy for $650 million)
Other news:
- CBIO +10.6% (Catalyst Biosciences and Mosaic Biosciences enter collaboration agreement)
- VKTX +8.6% (presents results from an eight-week study of VK2809 )
- VICL +5.7% (pursuing early stage development of a novel treatment for chronic hepatitis B virus based on its DNA and lipid-delivery technologies), EGO +5.2% (after 25% decline on mine update)
- ALXN +5.2% (receives FDA approval for Soliris)
- TNDM +4.6% (continued strength; also Armistice Capital discloses 4.99% passive stake)
- IPXL +3.2% (received final FDA approval on its Abbreviated ANDA for a generic version of Renvela (sevelamer carbonate) tablets, 800 mg; co has immediately initiated commercialization activities)
- DEST +3.1% (continued strength)
- ZEAL +2.4% (granted orphan drug designation by the FDA for glepaglutide for the treatment of short bowel syndrome)
- INO +2.2% (announces results of a study in which a DNA vaccine provided 100% protection for non-human primates challenged with a lethal dose of the Lassa fever virus)
- DE +1.6% (in sympathy with CAT)
- ICPT +1.4% (announces positive results from phase 2 AESOP trial evaluating OCA for treatment of patients with primary sclerosing cholangitis - met the primary endpoint)
- CNHI +1.3% (in sympathy with CAT)
- SPPI +1.2% (initiated with a Buy at Guggenheim)
Analyst comments:
- CRIS +8.9% (initiated with a Buy at Guggenheim; tgt $7)
- SCYX +8.2% (initiated with a Buy at Guggenheim; tgt $6)
- PRTY +2.7% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- CTMX +2.5% (initiated with a Overweight at Cantor Fitzgerald)
- HAS +1.6% (upgraded to Overweight from Equal Weight at Barclays)
- DK +1.3% (upgraded to Outperform from Neutral at Macquarie)
- PQG +0.8% (initiated with a Buy at Nomura, among others)
- CELG +0.7% (initiated with a Buy at Guggenheim)